GILEAD SCIENCES, INC.

GILD · CIK 0000882095

19 fiscal years · 68 SEC filings · every number carries its receipt

Revenue (FY)

$29.44B2.4%

FY2025

Net income (FY)

$8.51B1,672.9%

FY2025

Free cash flow (FY)

$9.46B8.2%

FY2025

Diluted EPS (FY)

$6.781,684.2%

FY2025

The story, charted

The shape of the business

FY2007–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 7.0× since FY2007 · net margin 37.5% → 28.9%

MarginsNet marginFCF margin

FY2025: net 28.9% · free cash flow 32.1% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $10.02B operating cash − $563.0M capex = $9.46B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity 46% (FY2008) → 37% (FY2025) · on assets 14.4%

The receipts

Financial statements

Annual Quarterly (as reported)

USD in millions except per-share and share counts. Every value links to the filing it came from — hover for the us-gaap tag, click for the 10-K/10-Q on sec.gov.

USD millions	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022
Revenue	6,960	7,769	7,082	6,667	7,545	6,954	6,686	7,051	6,599	6,352	7,042	6,260
Net income	2,021	3,052	1,960	1,315	1,253	1,614	(4,170)	2,180	1,045	1,010	1,789	1,144
Diluted EPS	1.61	2.43	1.56	1.04	1.00	1.29	(3.34)	1.73	0.83	0.80	1.42	0.91
Diluted shares	1,254	1,254	1,255	1,259	1,254	1,251	1,247	1,257	1,258	1,261	1,261	1,260
Operating cash flow	2,544	—	—	1,757	—	—	2,219	—	—	1,744	—	—
Capital expenditures	117	—	—	104	—	—	105	—	—	109	—	—
Free cash flow	2,427	—	—	1,653	—	—	2,114	—	—	1,635	—	—
Cash & equivalents	7,628	7,330	5,144	7,926	5,037	2,772	4,718	5,705	5,704	4,936	4,699	4,739
Total assets	56,278	58,533	55,721	56,434	54,525	53,579	56,292	62,373	62,337	61,876	62,557	62,870
Shareholders' equity	23,515	21,540	19,674	19,162	18,475	18,281	17,539	22,314	21,158	20,997	21,081	20,236

Figures as reported in SEC filings, normalized by stonks with the tag mapping shown on hover; missing tags render as “—”, never as zero. Free cash flow is derived (operating cash flow − capex) with both parents recorded in its lineage. Quarterly view shows as-reported 10-Q periods; Q4 synthesis ships in Phase 1. See methodology.